[go: up one dir, main page]

AU2002224322A1 - Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease - Google Patents

Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease

Info

Publication number
AU2002224322A1
AU2002224322A1 AU2002224322A AU2432202A AU2002224322A1 AU 2002224322 A1 AU2002224322 A1 AU 2002224322A1 AU 2002224322 A AU2002224322 A AU 2002224322A AU 2432202 A AU2432202 A AU 2432202A AU 2002224322 A1 AU2002224322 A1 AU 2002224322A1
Authority
AU
Australia
Prior art keywords
peptiderelease
dipeptide
amyloid
lactam
inhibiting beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224322A
Inventor
Thomas Mitchell Koenig
David Mitchell
Jeffrey Scott Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002224322A1 publication Critical patent/AU2002224322A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl-1-(L-alaninyl)-(S)-1-amino-3-methyl-4,5,6,7-tetrahydro-2H-3-benzazepin-2-one anhydrate, compositions thereof, and methods for using the same, processes for making the same, and processes for making intermediate thereof.
AU2002224322A 2000-11-17 2001-11-02 Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease Abandoned AU2002224322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24965500P 2000-11-17 2000-11-17
US60/249,655 2000-11-17
PCT/US2001/027796 WO2002040508A2 (en) 2000-11-17 2001-11-02 Lactam dipeptide and its use in inhibiting beta-amyloid peptide release

Publications (1)

Publication Number Publication Date
AU2002224322A1 true AU2002224322A1 (en) 2002-05-27

Family

ID=22944432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224322A Abandoned AU2002224322A1 (en) 2000-11-17 2001-11-02 Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease

Country Status (8)

Country Link
EP (1) EP1345955B1 (en)
JP (1) JP2005538031A (en)
AT (1) ATE405577T1 (en)
AU (1) AU2002224322A1 (en)
CA (1) CA2425558C (en)
DE (1) DE60135489D1 (en)
ES (1) ES2311561T3 (en)
WO (1) WO2002040508A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
JP5590769B2 (en) 2004-07-27 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Genetically modified host cells and methods of using the host cells for producing isoprenoid compounds
RU2404968C2 (en) 2005-04-08 2010-11-27 Дайити Санкио Компани, Лимитед Pyridyl dimethylsulphonic derivative
JP5198877B2 (en) * 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション Method for producing benzazepinones
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
CN102690231B (en) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 Method for synthesizing potential drug of Semagacestat for treating Alzheimer disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
CN1321155A (en) * 1998-08-07 2001-11-07 史密丝克莱恩比彻姆有限公司 Process for preparation of non-crystalline anhydrate form of paroxetine hydrochloride

Also Published As

Publication number Publication date
ES2311561T3 (en) 2009-02-16
WO2002040508A3 (en) 2003-03-27
CA2425558A1 (en) 2002-05-23
DE60135489D1 (en) 2008-10-02
ATE405577T1 (en) 2008-09-15
EP1345955B1 (en) 2008-08-20
CA2425558C (en) 2012-01-03
WO2002040508A2 (en) 2002-05-23
EP1345955A2 (en) 2003-09-24
JP2005538031A (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2002047671A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
YU15299A (en) Pharmaceutical compositions
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
ZA989560B (en) Compositions containing an Ó 1,2-fucose linkage and uses thereof.
BG101194A (en) New heteroaryl oxazolidinons
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
WO2002040451A3 (en) Lactam compound
AU5652698A (en) (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
ZA99733B (en) Ophthalmic composition.
AU2002224322A1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease
AU2253100A (en) Compositions obtained from (mangifera indica l.)
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2001259037A1 (en) Hydrogenated block copolymer compositions
IL139604A0 (en) Novel peptides
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
ZA200006118B (en) Novel composition.
ZA979643B (en) Heterocyclic compounds, compositions and uses.
ZA979642B (en) Heterocyclic compounds, compositions and uses.
ZA979649B (en) Heterocyclic compounds, compositions and uses.
ZA979644B (en) Heterocyclic compounds, compositions and uses.
MXPA02007005A (en) PSEUDOPOLYMORPH OF ()CIS2(2CHLOROPHENYL)5, 7DIHYDROXY8[4R(3SHYDROXY1METHYL)PIPERIDINYL]4Hminu s;1BENZOPYRAN4ONE.
PL353952A1 (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one